Lonza to Procure Roche’s California-based Biologics Facility

Lonza has revealed plans to procure the Genentech biologics facility situated in California from Roche for just over $1 billion.  

This addition of the California based site aims to bolster the company’s capacity for extensive biologics production, addressing the needs of clients with established commercial products and ongoing molecule development.  

Approximately 750 employees of Genentech are anticipated to receive offers of employment from Lonza subsequent to the completion of the agreement.  

The head chief of Biologics at Lonza, Jean-Christophe Hyvert, stated, “The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our Biologics division.”  

Hyvert went on to add, “In combining this with the strong legacy of the Vacaville facility, its highly skilled colleague community, and its proven track record on quality, we are excited to take our leading large-scale mammalian offering to its next chapter of growth.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.